IL290192A - Nitanin analogs and their use in the treatment of chronic and acute pain - Google Patents
Nitanin analogs and their use in the treatment of chronic and acute painInfo
- Publication number
- IL290192A IL290192A IL290192A IL29019222A IL290192A IL 290192 A IL290192 A IL 290192A IL 290192 A IL290192 A IL 290192A IL 29019222 A IL29019222 A IL 29019222A IL 290192 A IL290192 A IL 290192A
- Authority
- IL
- Israel
- Prior art keywords
- nitenin
- chronic
- treatment
- acute pain
- analogue compounds
- Prior art date
Links
- 208000002193 Pain Diseases 0.000 title 2
- 208000000094 Chronic Pain Diseases 0.000 title 1
- YHLJEGITRQRPJZ-UHFFFAOYSA-N Nitenin Natural products C1C(=CCCC2=COC=C2)C(=O)OC1C=C(C)CCCC=1C=COC=1 YHLJEGITRQRPJZ-UHFFFAOYSA-N 0.000 title 1
- 208000005298 acute pain Diseases 0.000 title 1
- 230000001684 chronic effect Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- LUGSEMDQUBBXEJ-UHFFFAOYSA-N nitenin Natural products O1C2=C(CCC(C)(C)O)C(OC)=CC(OC)=C2CCC1C1=CC=CC=C1 LUGSEMDQUBBXEJ-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D307/28—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/36—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PT11568519 | 2019-07-31 | ||
| PCT/IB2020/056915 WO2021019373A1 (en) | 2019-07-31 | 2020-07-22 | Nitenin analogue compounds and their use in the treatment of chronic and acute pain |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL290192A true IL290192A (en) | 2022-03-01 |
Family
ID=72240450
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL290192A IL290192A (en) | 2019-07-31 | 2022-01-27 | Nitanin analogs and their use in the treatment of chronic and acute pain |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US12336977B2 (https=) |
| EP (1) | EP4003984A1 (https=) |
| JP (1) | JP2022544057A (https=) |
| CN (1) | CN114616230A (https=) |
| AU (1) | AU2020320115A1 (https=) |
| CA (1) | CA3149175A1 (https=) |
| IL (1) | IL290192A (https=) |
| MX (1) | MX2022001186A (https=) |
| WO (1) | WO2021019373A1 (https=) |
| ZA (1) | ZA202201154B (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4003984A1 (en) | 2019-07-31 | 2022-06-01 | Sea4Us - Biotecnologia e Recursos Marinhos, Lda. | Nitenin analogue compounds and their use in the treatment of chronic and acute pain |
| CN116115739B (zh) * | 2022-12-29 | 2024-01-09 | 天津市肿瘤医院（天津医科大学肿瘤医院） | 胃动素及其受体激动剂的应用 |
| WO2026013449A2 (en) * | 2024-07-11 | 2026-01-15 | Sea4Us - Biotecnologia E Recursos Marinhos, Sa | Oxazolidone-derived compounds and their use in the treatment of chronic and acute pain |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7375136B2 (en) | 2001-03-08 | 2008-05-20 | Emory University | pH-dependent NMDA receptor antagonists |
| GB0305149D0 (en) * | 2003-03-07 | 2003-04-09 | Cambridge Biotechnology Ltd | Compounds for the treatment of pain |
| WO2007009462A2 (en) | 2005-07-15 | 2007-01-25 | Region Hovedstaden V/Glostrup Hospital | Treatment of migraine and headaches |
| ES2345527B1 (es) | 2008-10-08 | 2011-09-08 | Hospital Clinic I Provincial De Barcelona | Sustancias bloqueadoras de los canales kv 1.3 para el tratamiento de enfermedades asociadas a hiperplasia de la intima. |
| KR101939401B1 (ko) | 2011-11-10 | 2019-01-16 | 가천대학교 산학협력단 | 단핵식세포계 세포의 ａｇｅ-알부민 합성 또는 분비 저해제를 유효성분으로 포함하는 허혈성 심장질환 예방 또는 치료용 조성물 |
| CN106537149A (zh) * | 2014-04-01 | 2017-03-22 | 宝洁公司 | 用于筛选色氨酸通道的方法 |
| DK3126330T3 (en) | 2014-04-04 | 2019-04-23 | Pfizer | BICYCLE-FUSED HETEROARYL OR ARYL COMPOUNDS AND USE THEREOF AS IRAC4 INHIBITORS |
| CN106146530A (zh) * | 2015-04-14 | 2016-11-23 | 中国科学院生态环境研究中心 | 一种合成cephalosporolides E,F,H,I的新方法 |
| EP4003984A1 (en) | 2019-07-31 | 2022-06-01 | Sea4Us - Biotecnologia e Recursos Marinhos, Lda. | Nitenin analogue compounds and their use in the treatment of chronic and acute pain |
-
2020
- 2020-07-22 EP EP20761628.5A patent/EP4003984A1/en active Pending
- 2020-07-22 CN CN202080057704.6A patent/CN114616230A/zh active Pending
- 2020-07-22 JP JP2022506029A patent/JP2022544057A/ja active Pending
- 2020-07-22 CA CA3149175A patent/CA3149175A1/en active Pending
- 2020-07-22 AU AU2020320115A patent/AU2020320115A1/en active Pending
- 2020-07-22 MX MX2022001186A patent/MX2022001186A/es unknown
- 2020-07-22 WO PCT/IB2020/056915 patent/WO2021019373A1/en not_active Ceased
- 2020-07-22 US US17/631,135 patent/US12336977B2/en active Active
-
2022
- 2022-01-25 ZA ZA2022/01154A patent/ZA202201154B/en unknown
- 2022-01-27 IL IL290192A patent/IL290192A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3149175A1 (en) | 2021-02-04 |
| ZA202201154B (en) | 2024-02-28 |
| CN114616230A (zh) | 2022-06-10 |
| AU2020320115A1 (en) | 2022-02-24 |
| WO2021019373A4 (en) | 2021-03-25 |
| US12336977B2 (en) | 2025-06-24 |
| MX2022001186A (es) | 2022-05-11 |
| JP2022544057A (ja) | 2022-10-17 |
| WO2021019373A1 (en) | 2021-02-04 |
| EP4003984A1 (en) | 2022-06-01 |
| US20220288017A1 (en) | 2022-09-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL281999A (en) | YAP/TAZ-TEAD interaction inhibitors and their use in cancer therapy | |
| IL290192A (en) | Nitanin analogs and their use in the treatment of chronic and acute pain | |
| ES3064839T3 (en) | Combination of cannabidiol and buprenorphine and its use for the treatment of chronic pain | |
| IL289167A (en) | The history of 2h-indazole and their use in the treatment of diseases | |
| IL284053A (en) | New compounds and their use in therapy | |
| ZA202307970B (en) | Compounds for use in the treatment and prevention of covid- 19 | |
| IL283937A (en) | Combined treatment with raf inhibitor and cdk4/6 inhibitor for use in cancer treatment | |
| GB201918879D0 (en) | Treatment of chronic pain | |
| IL277805A (en) | Use of gaboksadol in the treatment of substance use disorders | |
| IL275132A (en) | C5AR inhibitors for use in the treatment of iatrogenic pain caused by chemotherapy | |
| GB2574747B (en) | Use of lambda interferons in the treatment of obesity-related disorders and related diseases | |
| IL282718A (en) | Compounds for use in the treatment or prevention of pain, inflammation and/or autoimmune diseases | |
| ZA202006886B (en) | R-fadrozole for use in the treatment of aldostonerism | |
| PL3937949T3 (pl) | Fitoekdyzony i ich pochodne do ich zastosowania w leczeniu upośledzenia funkcji oddechowych | |
| SG11202105276TA (en) | Oligo-benzamide analogs and their use in cancer treatment | |
| PL3713590T3 (pl) | Ludzka beta 2 defensyna do stosowania w zapobieganiu i leczeniu choroby przeszczep przeciwko gospodarzowi | |
| PL3442557T3 (pl) | Lek do skutecznej kontroli ostrego i/lub przewlekłego bólu oraz sposób jego podawania | |
| IL284298A (en) | Compounds for use as therapeutically active substances in the treatment and/or prevention of neuroretinal diseases | |
| GB2581035B (en) | Novel compounds and their use in therapy | |
| AU2019900258A0 (en) | Pyran compounds and their use in the treatment of pain | |
| GB201914640D0 (en) | Novel compounds and their use in therapy | |
| GB201913450D0 (en) | Novel compounds and their use in therapy | |
| GB201913448D0 (en) | Novel compounds and their use in therapy | |
| GB2574944B (en) | Methods and compositions for the treatment of pain and/or inflammation | |
| GB201909790D0 (en) | Novel compounds and their use in therapy |